JP2020504747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504747A5 JP2020504747A5 JP2019534709A JP2019534709A JP2020504747A5 JP 2020504747 A5 JP2020504747 A5 JP 2020504747A5 JP 2019534709 A JP2019534709 A JP 2019534709A JP 2019534709 A JP2019534709 A JP 2019534709A JP 2020504747 A5 JP2020504747 A5 JP 2020504747A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- methyl
- pyridin
- imidazole
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 55
- 150000001875 compounds Chemical class 0.000 claims 41
- -1 NH 2 Inorganic materials 0.000 claims 36
- 125000000623 heterocyclic group Chemical group 0.000 claims 24
- 125000000217 alkyl group Chemical group 0.000 claims 21
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 10
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- OJHWPOJTJKJBLA-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-benzimidazole Chemical compound C1C=CC=C2NCNC21 OJHWPOJTJKJBLA-UHFFFAOYSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 2
- JQTMGOLZSBTZMS-UHFFFAOYSA-N 4-methylpiperazine-1-carbaldehyde Chemical compound CN1CCN(C=O)CC1 JQTMGOLZSBTZMS-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 150000002460 imidazoles Chemical class 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- GWZRZYQFXWGKIQ-UHFFFAOYSA-N 2-(2-amino-6-methylpyrimidin-4-yl)sulfanyl-n-methylacetamide Chemical compound CNC(=O)CSC1=CC(C)=NC(N)=N1 GWZRZYQFXWGKIQ-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- UHYVUSGJRCYGIS-UHFFFAOYSA-N 5-fluoro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-8-yl)-N-[5-[(4-methylpiperazin-1-yl)methyl]pyrimidin-2-yl]pyrimidin-2-amine Chemical compound FC=1C(=NC(=NC=1)NC1=NC=C(C=N1)CN1CCN(CC1)C)C1=CC2=C(N=C3N2C(CCC3)C)C(=C1)F UHYVUSGJRCYGIS-UHFFFAOYSA-N 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- SDUUDIZDGDPGHT-UHFFFAOYSA-N N-[5-(4-cyclopropylpiperazin-1-yl)pyridin-2-yl]-5-fluoro-4-(9-fluoro-4-methyl-3,4-dihydro-1H-[1,4]oxazino[4,3-a]benzimidazol-7-yl)pyrimidin-2-amine Chemical compound C1(CC1)N1CCN(CC1)C=1C=CC(=NC=1)NC1=NC=C(C(=N1)C1=CC2=C(N=C3COCC(N32)C)C(=C1)F)F SDUUDIZDGDPGHT-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 206010024627 liposarcoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016111457 | 2016-12-22 | ||
| CNPCT/CN2016/111457 | 2016-12-22 | ||
| CN2017080661 | 2017-04-14 | ||
| CNPCT/CN2017/080661 | 2017-04-14 | ||
| PCT/CN2017/117950 WO2018113771A1 (en) | 2016-12-22 | 2017-12-22 | Benzimidazole derivatives, preparation methods and uses theirof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504747A JP2020504747A (ja) | 2020-02-13 |
| JP2020504747A5 true JP2020504747A5 (enExample) | 2021-01-14 |
| JP7105781B2 JP7105781B2 (ja) | 2022-07-25 |
Family
ID=62624617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534709A Active JP7105781B2 (ja) | 2016-12-22 | 2017-12-22 | ベンズイミダゾール誘導体、調製方法およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11053238B2 (enExample) |
| EP (1) | EP3559000B1 (enExample) |
| JP (1) | JP7105781B2 (enExample) |
| KR (1) | KR102543603B1 (enExample) |
| CN (1) | CN110234652B (enExample) |
| AU (1) | AU2017379041B2 (enExample) |
| CA (1) | CA3047876C (enExample) |
| DK (1) | DK3559000T3 (enExample) |
| ES (1) | ES2917377T3 (enExample) |
| TW (1) | TWI732083B (enExample) |
| WO (1) | WO2018113771A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106608879A (zh) * | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| WO2019035008A1 (en) | 2017-08-15 | 2019-02-21 | Beijing Xuanyi Pharmasciences Co., Ltd. | INHIBITORS OF CDK4 / 6 AND THEIR USE |
| US11174252B2 (en) | 2018-02-15 | 2021-11-16 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
| BR112020026052A2 (pt) * | 2018-06-21 | 2021-03-23 | Betta Pharmaceuticals Co., Ltd | forma de cristal do composto para a inibição da atividade de cdk4/6 e seu uso |
| WO2020224568A1 (en) * | 2019-05-05 | 2020-11-12 | Qilu Regor Therapeutics Inc. | Cdk inhibitors |
| CN111138455B (zh) * | 2020-01-16 | 2022-03-04 | 郑州大学 | 一种手性四氢呋喃并恶嗪稠合苯并咪唑衍生物及其制备方法和用途 |
| CN115427414A (zh) * | 2020-04-28 | 2022-12-02 | 贝达药业股份有限公司 | 稠环化合物及其在医药上的应用 |
| KR102269420B1 (ko) | 2020-09-18 | 2021-06-24 | 전용석 | 긴급대피용 마스크장치 |
| AR124154A1 (es) | 2020-11-27 | 2023-02-22 | Rhizen Pharmaceuticals Ag | Inhibidores de cdk |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN120682245A (zh) * | 2021-02-03 | 2025-09-23 | 江苏恒瑞医药股份有限公司 | 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途 |
| CN112979567B (zh) * | 2021-03-05 | 2023-07-18 | 中国医科大学 | Cdk12小分子抑制剂的化合物及其应用 |
| WO2022199656A1 (zh) * | 2021-03-24 | 2022-09-29 | 贝达药业股份有限公司 | 药物组合、包含其的试剂盒及其用途 |
| WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
| JP2025528074A (ja) * | 2022-08-01 | 2025-08-26 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 縮合三環系誘導体の結晶型及び調製方法 |
| WO2025016439A1 (zh) * | 2023-07-19 | 2025-01-23 | 浙江同源康医药股份有限公司 | 用作cdk2/4蛋白激酶抑制剂的化合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8852901A1 (es) * | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| JP5944823B2 (ja) | 2010-07-02 | 2016-07-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9878994B2 (en) | 2014-07-24 | 2018-01-30 | Beta Pharma Inc. | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof |
| TW201710257A (zh) | 2015-04-17 | 2017-03-16 | 艾伯維有限公司 | Ｔｎｆ信號傳遞之三環調節劑 |
| TWI696617B (zh) * | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
| CN105153119B (zh) | 2015-09-11 | 2019-01-01 | 广州必贝特医药技术有限公司 | 吡啶嘧啶胺类化合物或吡啶吡啶胺类化合物及其应用 |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
-
2017
- 2017-12-22 KR KR1020197020604A patent/KR102543603B1/ko active Active
- 2017-12-22 TW TW106145306A patent/TWI732083B/zh active
- 2017-12-22 CA CA3047876A patent/CA3047876C/en active Active
- 2017-12-22 DK DK17882916.4T patent/DK3559000T3/da active
- 2017-12-22 EP EP17882916.4A patent/EP3559000B1/en active Active
- 2017-12-22 JP JP2019534709A patent/JP7105781B2/ja active Active
- 2017-12-22 US US16/471,415 patent/US11053238B2/en active Active
- 2017-12-22 AU AU2017379041A patent/AU2017379041B2/en active Active
- 2017-12-22 ES ES17882916T patent/ES2917377T3/es active Active
- 2017-12-22 CN CN201780078241.XA patent/CN110234652B/zh active Active
- 2017-12-22 WO PCT/CN2017/117950 patent/WO2018113771A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504747A5 (enExample) | ||
| AU2015353210B2 (en) | 2-aminopyrimidine compound and pharmaceutical composition and use thereof | |
| WO2022157629A1 (en) | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer | |
| CA3047876C (en) | Benzimidazole derivatives, preparation methods and uses thereof | |
| ES2904544T3 (es) | Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos | |
| RU2018104702A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
| CN114430739A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| RU2009125897A (ru) | Ингибиторы фосфоинозитид-3-киназы и способы их применения | |
| JP2020503299A5 (enExample) | ||
| HRP20200854T1 (hr) | Novi biciklički inhibitori bromodomene | |
| JP2011507854A5 (enExample) | ||
| CA2997039C (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| JP2011510995A5 (enExample) | ||
| RU2018134981A (ru) | Конъюгаты, содержащие ингибиторы RIPK2 | |
| JP2018531983A (ja) | タンパク質分解誘導キメラ化合物ならびにその調製方法および使用方法 | |
| JP2012501312A5 (enExample) | ||
| JP2016106112A (ja) | ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用 | |
| JP2016525078A5 (enExample) | ||
| JP2019514878A5 (enExample) | ||
| JP2010512338A5 (enExample) | ||
| US8022209B2 (en) | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | |
| HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
| JP2018518522A5 (enExample) | ||
| JP2019505594A5 (enExample) | ||
| FI4419526T3 (fi) | Heterosyklisiä yhdisteitä käytettäväksi syövän hoidossa |